Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Investing in Alzheimer’s research in 2022on June 28, 2022 at 4:13 am
Alzheimer's disease is the most common form of dementia and impacts a person's memory and other cognitive functions. Millions of people suffer from Alzheimer's worldwide and the number of people ...
- Research focuses on diagnosing, lessening effects of Alzheimer’s diseaseon June 27, 2022 at 9:07 pm
More than 6 million Americans are living with Alzheimer’s disease, costing the nation $321 billion in 2022, according to the Alzheimer’s Association. A variety of studies and pilot programs are ...
- Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Valueon June 27, 2022 at 5:00 pm
Today’s treatments for AD are limited and unsatisfactory. This article explores how a new drug, NVG-291, could offer an alternative approach – not trying to cure the disease but actually repair the ...
- Elvis fan, 74, with Alzheimer’s comes ‘back to life’ when he hears his favorite songson June 27, 2022 at 4:53 pm
The debilitating affliction has left him struggling to verbally communicate with his family — but Elvis gets him to bust some “crazy moves,” his daughter says.
- COVID-19 may increase risk of Alzheimer's, Parkinson's, stroke: studyon June 27, 2022 at 4:06 pm
A Danish study discovered that patients leaving the hospital after a COVID-19 infection were more likely to have a higher risk of Alzheimer's and Parkinson's.
- The Flu Vaccine May Help Keep Alzheimer's at Bayon June 27, 2022 at 2:51 pm
A study found that adults over 65 vaccinated for the flu were noticeably less likely to develop Alzheimer's over a four year span than those unvaccinated.
- Local doctor discusses early signs of Alzheimer'son June 27, 2022 at 2:20 pm
Dr. Kyan Younes, neurologist with Stanford Health Care, discusses the symptoms of and treatments for Alzheimer's disease, the most common cause of dementia ...
- Local doctor raises awareness about Alzheimer...on June 27, 2022 at 1:12 pm
Watch "alzheimers disease kyan younes stanford health care", a video on CBSNews.com. View more videos and watch CBS News, a live news stream featuring original CBS News reporting.
- Study: Medicare could waste up to $605M on Alzheimer's drug vialson June 27, 2022 at 12:54 pm
The vials containing an expensive, controversial drug for Alzheimer's disease are fixed in size, yet the amount required by patients varies widely. This issue alone could waste $605 million in ...
via Bing News